Liminatus Pharma, Inc. Class A Common Stock (LIMN) - Net Assets
Based on the latest financial reports, Liminatus Pharma, Inc. Class A Common Stock (LIMN) has net assets worth $-1.65 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.34 Million) and total liabilities ($2.99 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read total liabilities of Liminatus Pharma, Inc. Class A Common St for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-1.65 Million |
| % of Total Assets | -122.6% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 413.36 |
Liminatus Pharma, Inc. Class A Common Stock - Net Assets Trend (2021–2024)
This chart illustrates how Liminatus Pharma, Inc. Class A Common Stock's net assets have evolved over time, based on quarterly financial data. Also explore LIMN total asset value for the complete picture of this company's asset base.
Annual Net Assets for Liminatus Pharma, Inc. Class A Common Stock (2021–2024)
The table below shows the annual net assets of Liminatus Pharma, Inc. Class A Common Stock from 2021 to 2024. For live valuation and market cap data, see market cap of Liminatus Pharma, Inc. Class A Common St.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-15.87 Million | -48.42% |
| 2023-12-31 | $-10.69 Million | -926.20% |
| 2022-12-31 | $1.29 Million | -99.49% |
| 2021-12-31 | $254.87 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Liminatus Pharma, Inc. Class A Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 361365000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.76 Million | % |
| Other Comprehensive Income | $-160.68K | % |
| Other Components | $51.80K | % |
| Total Equity | $-15.87 Million | 100.00% |
Liminatus Pharma, Inc. Class A Common Stock Competitors by Market Cap
The table below lists competitors of Liminatus Pharma, Inc. Class A Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
C&C Group plc
LSE:CCR
|
$5.33 Million |
|
Golden State Mining Ltd
AU:GSM
|
$5.33 Million |
|
DXN Ltd
AU:DXN
|
$5.34 Million |
|
Brera Holdings PLC Class B Ordinary Shares
NASDAQ:BREA
|
$5.34 Million |
|
Wickes Group PLC
LSE:WIX
|
$5.33 Million |
|
Zephyr Minerals Ltd
V:ZFR
|
$5.33 Million |
|
Wirtek A/S
CO:WIRTEK
|
$5.33 Million |
|
Volt Carbon Technologies Inc
V:VCT
|
$5.33 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Liminatus Pharma, Inc. Class A Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -10,692,784 to -15,869,899, a change of -5,177,115.
- Net loss of 2,904,299 reduced equity.
- Share repurchases of 1,802,869 reduced equity.
- Other comprehensive income decreased equity by 160,677.
- Other factors decreased equity by 309,270.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-2.90 Million | -18.3% |
| Share Repurchases | $1.80 Million | -11.36% |
| Other Comprehensive Income | $-160.68K | -1.01% |
| Other Changes | $-309.27K | -1.95% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Liminatus Pharma, Inc. Class A Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $7.39 | $0.21 | x |
| 2022-12-31 | $0.04 | $0.21 | x |
| 2023-12-31 | $-1.33 | $0.21 | x |
| 2024-12-31 | $-2.21 | $0.21 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Liminatus Pharma, Inc. Class A Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-56.13%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 1.71% | 0.00% | 0.00x | 1.08x | $-21.12 Million |
| 2022 | -226.24% | 0.00% | 0.00x | 11.97x | $-3.06 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-156.94K |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.32 Million |
Industry Comparison
This section compares Liminatus Pharma, Inc. Class A Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Liminatus Pharma, Inc. Class A Common Stock (LIMN) | $-1.65 Million | 1.71% | N/A | $5.33 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Liminatus Pharma, Inc. Class A Common Stock
Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies. It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPa blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis. The company was founded in 201… Read more